Literature DB >> 32113187

Improved Mycobacterium tuberculosis clearance after the restoration of IFN-γ+ TNF-α+ CD4+ T cells: Impact of PD-1 inhibition in active tuberculosis patients.

Divya Kamboj1, Pushpa Gupta2, Mandira Varma Basil3, Anant Mohan4, Randeep Guleria4, Anuj Bhatnagar5, Girija Mehta1, Prabin Kumar1, Abhinav Saurabh1, Rakesh Deepak1, Deepshi Thakral1, Pragya Misra1, Rati Tandon6, Umesh D Gupta2, Dipendra Kumar Mitra1.   

Abstract

Prolonged therapy, drug toxicity, noncompliance, immune suppression, and alarming emergence of drug resistance necessitate the search for therapeutic vaccine strategies for tuberculosis (TB). Such strategies ought to elicit not only IFN-γ, but polyfunctional response including TNF-α, which is essential for protective granuloma formation. Here, we investigated the impact of PD-1 inhibition in facilitating protective polyfunctional T cells (PFTs), bacillary clearance, and disease resolution. We have observed PD-1 inhibition preferentially rescued the suppressed PFTs in active tuberculosis patients. In addition, polyfunctional cytokine milieu favored apoptosis of infected MDMs over necrosis with markedly reduced bacillary growth (≪CFU) in our in vitro monocyte-derived macrophages (MDMs) infection model. Furthermore, the animal study revealed a significant decline in the bacterial burden in the lungs and spleen of infected mice after in vivo administration of α-PD-1 along with antitubercular treatment. Our findings suggest that rescuing polyfunctional immune response by PD-1 inhibition works synergistically with antituberculosis chemotherapy to confer improved control over bacillary growth and dissemination. In summary, our data strongly indicate the therapeutic potential of α-PD-1 as adjunct immunotherapy that can rejuvenate suppressed host immunity and enhance the efficacy of candidate therapeutic vaccine(s).
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  PD-1; Treg cells; immunotherapy; polyfunctional T cells; tuberculosis

Year:  2020        PMID: 32113187     DOI: 10.1002/eji.201948283

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  TGFβ restricts expansion, survival, and function of T cells within the tuberculous granuloma.

Authors:  Benjamin H Gern; Kristin N Adams; Courtney R Plumlee; Caleb R Stoltzfus; Laila Shehata; Albanus O Moguche; Kathleen Busman-Sahay; Scott G Hansen; Michael K Axthelm; Louis J Picker; Jacob D Estes; Kevin B Urdahl; Michael Y Gerner
Journal:  Cell Host Microbe       Date:  2021-03-11       Impact factor: 21.023

2.  Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.

Authors:  Isabel Leroux-Roels; Gwenn Waerlop; Jessika Tourneur; Fien De Boever; Catherine Maes; Jacques Bruhwyler; Delphine Guyon-Gellin; Philippe Moris; Judith Del Campo; Paul Willems; Geert Leroux-Roels; Alexandre Le Vert; Florence Nicolas
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 3.  Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy.

Authors:  Ryan Ha; Yoav Keynan; Zulma Vanessa Rueda
Journal:  Front Cell Infect Microbiol       Date:  2022-09-07       Impact factor: 6.073

4.  Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium.

Authors:  Masayuki Nakajima; Masashi Matsuyama; Mio Kawaguchi; Sosuke Matsumura; Takumi Kiwamoto; Yosuke Matsuno; Yuko Morishima; Kazufumi Yoshida; Mingma Thsering Sherpa; Kai Yazaki; Ryota Tanaka; Naoko Okiyama; Masafumi Muratani; Yukio Ishii; Nobuyuki Hizawa
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.